AB InBev reports volume decline in Brazil and China, but beats profit expectations with price hikes and margin improvements.
Moderna plans major workforce reduction amid declining COVID vaccine sales, but aims to continue investing in science and expects multiple regulatory approvals in coming years.
AB InBev reports volume decline in Brazil and China, but beats profit expectations with price hikes and margin improvements.
Moderna plans major workforce reduction amid declining COVID vaccine sales, but aims to continue investing in science and expects multiple regulatory approvals in coming years.